

ERYTHROPOIETIN STIMULATING AGENTS: THERAPEUTIC APPLICATIONS AND GLOBAL MARKETS



PHM130A
January 2016

Aneesh Kumar
Project Analyst

ISBN: 1-62296-190-0



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	3
REASONS FOR DOING THE STUDY	3
SCOPE OF REPORT	3
INTENDED AUDIENCE	3
INFORMATION SOURCES	4
RESEARCH METHODOLOGY	4
ANALYSTS' CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
DEFINITION	11
ERYTHROPOIETIN AS A DRUG	12
DEVELOPMENTAL STAGES OF ERYTHROPOIETIN	12
APPLICATIONS OF ERYTHROPOIETIN	13
SIDE EFFECTS OF ERYTHROPOIETIN	14
CARDIOVASCULAR	15
HEMATOLOGIC	15
CENTRAL NERVOUS SYSTEM	15
PSYCHIATRIC	16
ONCOLOGIC	16
GASTROINTESTINAL	16
DERMATOLOGIC	16
PROS AND CONS OF MANUFACTURING METHODS:	16
PROS	16
CONS	16
CHAPTER 4 R&D DRUG PIPELINE	19
<i>TABLE 1 MAJOR EPO R & D DRUG PIPELINE BY TRIAL PHASE</i>	19
CHAPTER 5 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUG	21
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY CATEGORY	21
<i>TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 (\$ MILLIONS)</i>	21
<i>FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)</i>	21
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY TYPE	22

TOPIC	PAGE NO.
<i>TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	23
<i>FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)</i>	23
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE	25
<i>TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	25
<i>FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)</i>	25
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE	27
<i>TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	28
<i>FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)</i>	28
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION	29
<i>TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	30
<i>FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	30
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION	31
<i>TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	32
<i>FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)</i>	32
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION	34
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUG MARKET BY REGION	34
<i>TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	34
<i>FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)</i>	34
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION	36
<i>TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	36
<i>FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)</i>	37
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION	39
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION	39
<i>TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	39
<i>FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	40
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION	41
<i>TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	42
<i>FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	42
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY REGION	43

TOPIC	PAGE NO.
<i>TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	44
<i>FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)</i>	44
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY REGION	46
<i>TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	46
<i>FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)</i>	46
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION	49
<i>TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	49
<i>FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)</i>	49
GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION	52
<i>TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	52
<i>FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)</i>	52
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION	53
<i>TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	53
<i>FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)</i>	53
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION	56
<i>TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	56
<i>FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)</i>	57
GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION	59
<i>TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	59
<i>FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)</i>	60
GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY APPLICATION	62
<i>TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	62
<i>FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	62
GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY APPLICATION	63
<i>TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	64
<i>FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	64
GLOBAL MARKET FORECAST FOR DARBEPOETIN-ALFA BY APPLICATION	65
<i>TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	66

TOPIC	PAGE NO.
<i>FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	66
<i>GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION</i>	67
<i>TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	68
<i>FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	68
<i>GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY REGION</i>	69
<i>TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	69
<i>FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)</i>	69
<i>GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY APPLICATION</i>	70
<i>TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	71
<i>FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	71
<i>GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY REGION</i>	72
<i>TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	72
<i>FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)</i>	72
<i>GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY APPLICATION</i>	73
<i>TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	73
<i>FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	73
<i>GLOBAL MARKET FORECAST FOR EPREX DRUGS BY REGION</i>	75
<i>TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	75
<i>FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)</i>	75
<i>GLOBAL MARKET FORECAST FOR EPREX DRUGS BY APPLICATION</i>	77
<i>TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	78
<i>FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	78
<i>GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY REGION</i>	79
<i>TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	80
<i>FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)</i>	80
<i>GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY APPLICATION</i>	82
<i>TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	82
<i>FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	82
<i>GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY REGION</i>	84
<i>TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	84

TOPIC	PAGE NO.
<i>FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)</i>	84
GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY APPLICATION	86
<i>TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	87
<i>FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	87
GLOBAL MARKET FORECAST FOR MIRCERA DRUGS BY REGION	88
<i>TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	89
<i>FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)</i>	89
GLOBAL MARKET FORECAST FOR MIRCERA BY APPLICATION	91
<i>TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	91
<i>FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)</i>	91
CHAPTER 6 DRIVERS AND CHALLENGES	94
INCREASING CASES OF CHRONIC KIDNEY DISEASE	94
DIABETES	94
<i>FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)</i>	94
<i>FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)</i>	96
<i>FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)</i>	97
<i>FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)</i>	97
HYPERTENSION	98
<i>FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014</i>	98
<i>TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)</i>	100
<i>TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)</i>	101
<i>TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)</i>	102
<i>TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)</i>	102
INCREASING PREVALENCE OF CANCER	103
<i>FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)</i>	104
<i>FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%)</i>	105
<i>FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)</i>	106
<i>FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)</i>	107
<i>FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)</i>	108
<i>FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)</i>	109
<i>TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS</i>	111
RISK OF THROMBOSIS AND PURE RED CELL APLASIA (PRCA)	112

TOPIC	PAGE NO.
CARDIOVASCULAR PROBLEMS	112
THROMBOSIS IN CANCER PATIENTS	112
INCREASED TUMOR PROGRESSION	113
ZIVODUINE TREATED HIV INFECTED PATIENTS	113
PURE RED CELL APLASIA	113
INCREASING GENERIC COMPETITION	114
SYNTHETIC ERYTHROPOIETIN	114
TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY	114
CHAPTER 7 VENDOR LANDSCAPE AND COMPANY PROFILES	116
TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/\$ MILLIONS)	116
3SBIO INC.	117
TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	117
AMEGA BIOTECH	118
AMGEN INC.	118
TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE	119
TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS	119
TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 (\$ MILLIONS)	119
TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 (\$ MILLIONS)	120
TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	120
FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)	121
FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)	121
BIOCON	123
FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)	123
TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	124
FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)	124
BIOSIDUS	125
BLAUSIEGEL	126
CELON LABS	127
CENTER OF MOLECULAR IMMUNOLOGY	127
CHALVER LABORATORIES	128
CJ HEALTHCARE	128
CLARIS LIFESCIENCES	129
TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	129
DR. REDDY'S LABORATORIES.	130
FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)	130
TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)	131
EMCURE PHARMACEUTICALS	131
HINDUSTAN ANTIBIOTICS	132
HOSPIRA INC.	133
TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	134
FIGURE 50 HOSPIRA'S SALES BY REGION, 2014	134

TOPIC	PAGE NO.
<i>FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)</i>	135
INTAS BIOPHARMACEUTICAL LTD	136
<i>TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	136
<i>FIGURE 52 INTAS' SALES BY REGION, 2014 (%)</i>	137
JCR PHARMACEUTICALS CO. LTD.	137
<i>TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 (\$ MILLIONS)</i>	138
<i>FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)</i>	138
JOHNSON & JOHNSON	139
<i>TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 (\$ MILLIONS)</i>	139
<i>FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)</i>	140
<i>TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	141
LANDSTEINER SCIENTIFIC S.A. DE C.V.	141
LA RENON HEALTHCARE	141
LG LIFE SCIENCES	142
<i>TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)</i>	142
LUPIN LTD.	143
<i>TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	143
<i>FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)</i>	144
MEDICE DRUG PUTTER GMBH & CO. KG	145
NOVARTIS INTERNATIONAL AG	145
<i>TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	146
<i>FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)</i>	146
<i>FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)</i>	147
PANACEA BIOTEC	148
<i>TABLE 58 COMPOSITIONS OF ERYTHROPOETIN MANUFACTURED BY PANACEA</i>	148
<i>TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	148
<i>FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)</i>	149
PROBIOMED	150
RELIANCE LIFE SCIENCES	150
ROCHE	151
<i>TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 (\$ MILLIONS)</i>	152
<i>TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	152
<i>TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	153
<i>TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	154
RPG LIFE SCIENCES	154
<i>TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	155
<i>FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)</i>	155
<i>FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)</i>	156
SERUM INSTITUTE OF INDIA	157

TOPIC	PAGE NO.
SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.	157
SHANTHA BIOTECHNICS	158
STADA ARZNEIMITTEL AG	158
<i>TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	159
<i>FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)</i>	159
<i>FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 (\$ MILLIONS)</i>	160
SUN PHARMACEUTICAL INDUSTRIES LTD.	161
<i>TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	162
<i>FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)</i>	162
<i>FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)</i>	163
TEVA PHARMACEUTICAL INDUSTRIES LTD.	164
<i>TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)</i>	164
<i>FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)</i>	165
<i>FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)</i>	165
VHB LIFE SCIENCES LTD.	166
WOCKHARDT LIMITED	167
<i>FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)</i>	168
<i>TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)</i>	169
ZUVENTUS HEALTH CARE	169
ZYDUS CADILA HEALTHCARE	170
<i>TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)</i>	171
<i>FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)</i>	171

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	7
TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE	19
TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 (\$ MILLIONS)	21
TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	23
TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	25
TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	28
TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	30
TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	32
TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	34
TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	36
TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	39
TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	42
TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	44
TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	46
TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	49
TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	52
TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)	53
TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)	56
TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 (\$ MILLIONS)	59
TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	62
TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	64
TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	66
TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	68
TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	69
TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	71
TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	72

TABLE HEADING	PAGE NO.
TABLE 26 GLOBAL MARKET FOR PROCRT DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	73
TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	75
TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	78
TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	80
TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	82
TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	84
TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	87
TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	89
TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	91
TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)	100
TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)	101
TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)	102
TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)	102
TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS	111
TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/\$ MILLIONS)	116
TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	117
TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE	119
TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS	119
TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 (\$ MILLIONS)	119
TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 (\$ MILLIONS)	120
TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	120
TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	124
TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	129
TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)	131
TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	134
TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	136
TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 (\$ MILLIONS)	138
TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 (\$ MILLIONS)	139
TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	141
TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)	142

TABLE HEADING	PAGE NO.
TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	143
TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	146
TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA	148
TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	148
TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 (\$ MILLIONS)	152
TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 (\$ MILLIONS)	152
TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 (\$ MILLIONS)	153
TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	154
TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	155
TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	159
TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	162
TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS/%)	164
TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)	169
TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 (\$ MILLIONS)	171

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)	21
FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)	23
FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)	25
FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)	28
FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)	30
FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)	32
FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)	34
FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)	37
FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)	40
FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)	42
FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)	44
FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)	46
FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)	49
FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)	52
FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)	53
FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)	57
FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)	60
FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)	62
FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)	64
FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)	66
FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)	68
FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)	69
FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)	71
FIGURE 24 GLOBAL MARKET SHARE FOR PROCRT DRUGS BY REGION, 2015 AND 2020 (%)	72

FIGURE TITLE	PAGE NO.
FIGURE 25 GLOBAL MARKET SHARE FOR PROCRT DRUGS BY APPLICATION, 2015 AND 2020 (%)	73
FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)	75
FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%)	78
FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)	80
FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)	82
FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)	84
FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)	87
FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)	89
FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)	91
FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)	94
FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)	96
FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)	97
FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)	97
FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014	98
FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)	104
FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%)	105
FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)	106
FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)	107
FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)	108
FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)	109
FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)	121
FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)	121
FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)	123
FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)	124
FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)	130
FIGURE 50 HOSPIRA'S SALES BY REGION, 2014	134
FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)	135
FIGURE 52 INTAS' SALES BY REGION, 2014 (%)	137
FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)	138
FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)	140
FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)	144
FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)	146
FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)	147
FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)	149

FIGURE TITLE	PAGE NO.
FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)	155
FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)	156
FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)	159
FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 (\$ MILLIONS)	160
FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)	162
FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)	163
FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)	165
FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)	165
FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)	168
FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)	171